(Total Views: 655)
Posted On: 03/29/2021 9:09:51 AM
Post# of 145250
Ohm,
Correct, we need to bear in mind that HGEN did not power their trial for mortality end-point.
They say that will the data they have in-hand they would need app. 1800 patients for this (as opposed to app 6000 in Dexamethasone and app 4000 Tocilizumab) with a 80% power.
They obtained a Hazard ratio of 1.54 (p-value: 0.0365) in Ventilator-free survival.
I believe this is what we will have as PE in our CD-16 trial for Critical.
Correct, we need to bear in mind that HGEN did not power their trial for mortality end-point.
They say that will the data they have in-hand they would need app. 1800 patients for this (as opposed to app 6000 in Dexamethasone and app 4000 Tocilizumab) with a 80% power.
![176777509_PrimaryHGEN.13.jpg](https://investorshangout.com/images/MYImages/176777509_PrimaryHGEN.13.jpg)
They obtained a Hazard ratio of 1.54 (p-value: 0.0365) in Ventilator-free survival.
I believe this is what we will have as PE in our CD-16 trial for Critical.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)